Winson Y Cheung, Setareh Samimi, Kim Ma, Gregory John Knight, Shaqil Kassam, Bruce Colwell, Annie Beaudoin, Mark David Vincent, Mateya Trinkaus, Alain Filion, Katerine Marquis, Hatim Karachiwala, Timothy Asmis, Lucas Sideris, Rajvi J Wani, Elaine Ngan, Naila Inam, Yinhao Du, Leyla Nunez, Maria Eberg, Mistre Alemayehu, Pierre-Francois Meyer, Johanna Mancini, Carlye Cirone Morris
BACKGROUND: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer (mCRC). This study aimed to address gaps in real-world evidence (RWE) including patient characteristics, treatment safety (primary objective), and effectiveness (secondary objective) for first-line ABP 215 therapy in Canadian patients with mCRC. MATERIALS AND METHODS: Retrospective data were collected in 2 waves, at least 1 year (Wave 1) or 2 years (Wave 2) after commercial availability of ABP 215 at each participating site...
October 28, 2023: Clinical Colorectal Cancer